CSPC Innovation Pharmaceutical's Q3 Profit Plunges 98%

MT Newswires Live10-23

CSPC Innovation Pharmaceutical (SHE:300765) recorded a 98% decline in attributable profit in the third quarter to 2.3 million yuan from 116.9 million yuan a year prior, a Wednesday bourse filing by parent CSPC Pharmaceutical (HKG:1093) said.

Earnings per share were 0.002 yuan in the quarter, down from 0.0838 yuan in the corresponding period of last year.

The pharmaceutical company's revenue declined by 14% to 507.1 million yuan in the three months ended Sept. 30 from 592.9 million yuan in the year-ago period.

For the nine months ended Sept. 30, attributable profit and revenue plummeted 64% and 24% to 139.3 million yuan and 1.48 billion yuan, respectively.

Shares of CSPC Innovation Pharmaceutical closed 2% higher on Wednesday, while those of CSPC Pharmaceutical closed over 1% lower.

Price (HKD): $31.23, Change: $+0.61, Percent Change: +1.99%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment